Global GLP-1 Receptor Agonist Market Introduction and Overview
According to SPER Market Research, the Global GLP-1 Receptor Agonist Market is estimated to reach USD 266.54 billion by 2033 with a CAGR of 21.9%.
The report includes an in-depth analysis of the Global GLP-1 Receptor Agonist Market, including market size and trends, product mix, applications, and supplier analysis. A class of drugs known as GLP-1 receptor agonists is mostly used to treat type 2 diabetes and, more recently, obesity. They function similarly to glucagon-like peptide-1 (GLP-1), a hormone that inhibits glucagon release, slows stomach emptying, increases feelings of fullness, and raises insulin secretion in response to meals. These medications aid in better blood sugar regulation and can promote weight loss by improving insulin sensitivity and controlling hunger. Liraglutide and semaglutide are common examples that have also demonstrated cardiovascular benefits.
- In February 2024, Eli Lilly and Company announced that if Mounjaro, their extremely effective diabetes drug and obesity treatment, survives a continuing regulatory review, it might be introduced in India as early as the following year. This product should have a favorable effect on the growth of the Indian market.
- Even though it is having trouble meeting demand in its current territories, Novo Nordisk A/S announced in November 2023 that it would offer its very successful anti-obesity medication, Wegovy, in Japan on February 22. This would be the company's first Asian launch.
Market Opportunities and Challenges
Opportunities- The market is expected to be driven by the introduction of new GLP-1 receptor agonist pharmaceuticals, a robust pipeline of products for diabetes and obesity applications, and the high efficacy of these medications. To treat patients with type 2 diabetes, obesity, and cardio-metabolic disorders, Eccogen and AstraZeneca, for example, inked an exclusive licensing agreement in November 2023 for ECC5004, an experimental oral GLP-1 receptor agonist. According to the initial findings of a phase I trial, ECC5004 has a unique clinical profile, high tolerability, and encouraging decreases in body weight and glucose at all tested dose levels when compared to a placebo.
Challenges- Many challenges could hinder the market's expansion and accessibility for GLP-1 receptor agonists. Patient access is frequently hampered by the high cost of these drugs, particularly in areas with less extensive healthcare infrastructures. Concerns have also been raised regarding adverse effects, like gastrointestinal problems, which may discourage patients from following their treatment plan. The situation is made more challenging by competition from alternative treatments for diabetes and obesity, such as non-pharmacological approaches and newer drugs. The approval procedure for novel formulations might also be slowed by regulatory obstacles and the requirement for substantial clinical data to prove long-term safety and efficacy.
Market Competitive Landscape
The Global GLP-1 Receptor Agonist Market is highly consolidated. Some of the market key players are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Product, By Application, By Route of Administration, By Distribution Channel |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi. |
COVID-19 Impact on Global GLP-1 Receptor Agonist Market
The global market for GLP-1 receptor agonists was greatly impacted by the COVID-19 epidemic in a number of ways. At first, the interruption of medical services resulted in fewer patient visits and postponed diabetes and obesity diagnoses, which in turn reduced the number of new prescriptions for these drugs. GLP-1 receptor agonist availability was also impacted by supply chain disruptions, leading to shortages in certain areas. On the other hand, because those with diabetes were more vulnerable to COVID-19, the pandemic raised awareness of metabolic health and brought attention to the need to manage these disorders.
Key Target Audience:
- Healthcare Providers
- Patients with Type 2 Diabetes
- Obesity Patients
- Endocrinologists
- Diabetes Educators
- Pharmacists
- Insurance Companies
- Pharmaceutical Companies
Our in-depth analysis of the Global GLP-1 Receptor Agonist Market includes the following segments:
| By Product: | OzempicTrulicityMounjaroWegovyRybelsusSaxendaVictozaZepboundOther Products |
| By Application: | Type 2 Diabetes MellitusObesity |
| By Route of Administration: | ParenteralOral |
| By Distribution Channel: | Hospital PharmaciesRetail PharmaciesOnline Pharmacies |
Key Topics Covered in the Report:
- Global GLP-1 Receptor Agonist Market Size (FY’2024-FY’2033)
- Overview of Global GLP-1 Receptor Agonist Market
- Segmentation of Global GLP-1 Receptor Agonist Market By Product (Ozempic,k Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other)
- Segmentation of Global GLP-1 Receptor Agonist Market By Application (Type 2 Diabetes Mellitus, Obesity)
- Segmentation of Global GLP-1 Receptor Agonist Market By Route of Administration (Parenteral, Oral)
- Segmentation of Global GLP-1 Receptor Agonist Market By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- Statistical Snap of Global GLP-1 Receptor Agonist Market
- Expansion Analysis of Global GLP-1 Receptor Agonist Market
- Problems and Obstacles in Global GLP-1 Receptor Agonist Market
- Competitive Landscape in the Global GLP-1 Receptor Agonist Market
- Impact of COVID-19 and Demonetization on Global GLP-1 Receptor Agonist Market
- Details on Current Investment in Global GLP-1 Receptor Agonist Market
- Competitive Analysis of Global GLP-1 Receptor Agonist Market
- Prominent Players in the Global GLP-1 Receptor Agonist Market
- SWOT Analysis of Global GLP-1 Receptor Agonist Market
- Global GLP-1 Receptor Agonist Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global GLP-1 Receptor Agonist Market.
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global GLP-1 Receptor Agonist Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global GLP-1 Receptor Agonist Market
7. Global GLP-1 Receptor Agonist Market, By Product (USD Million) 2020-2033
7.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2020-2026
7.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Product, 2027-2033
7.3. Ozempic
7.4. Trulicity
7.5. Mounjaro
7.6. Wegovy
7.7. Rybelsus
7.8. Saxenda
7.9. Victoza
7.10. Zepbound
7.11. Other Products
8. Global GLP-1 Receptor Agonist Market, By Application (USD Million) 2020-2033
8.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2020-2026
8.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Application, 2027-2033
8.3. Type 2 Diabetes Mellitus
8.4. Obesity
9. Global GLP-1 Receptor Agonist Market, By Route of Administration (USD Million) 2020-2033
9.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2020-2026
9.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Route of Administration, 2027-2033
9.3. Parenteral
9.4. Oral
10. Global GLP-1 Receptor Agonist Market, By Distribution Channel (USD Million) 2020-2033
10.1. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2020-2026
10.2. Global GLP-1 Receptor Agonist Market Size, Share and Forecast, By Distribution Channel, 2027-2033
10.3. Hospital Pharmacies
10.4. Retail Pharmacies
10.5. Online Pharmacies
11. Global GLP-1 Receptor Agonist Market Forecast, 2020-2033 (USD Million)
11.1. Global GLP-1 Receptor Agonist Market Size and Market Share
12. Global GLP-1 Receptor Agonist Market, By Region, 2020-2033 (USD Million)
12.1. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2020-2026)
12.2. Global GLP-1 Receptor Agonist Market Size and Market Share By Region (2027-2033)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Qatar
12.5.4. South Africa
12.5.5. Egypt
12.5.6. Morocco
12.5.7. Nigeria
12.5.8. Rest of Middle-East and Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America
13. Company Profile
13.1. Eli Lilly and Company
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Sanofi
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Novo Nordisk A/S
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. AstraZeneca
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
